The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ICML 2025 | An update of the NP30179 trial: a single-arm study assessing glofitamab in R/R MCL
In this video, Tycel Phillips, MD, City of Hope, Duarte, CA, shares updates from the mantle cell lymphoma (MCL) cohort of the Phase I/II NP30179 trial (NCT03075696) assessing glofitamab. Dr Phillips highlights the encouraging results observed with glofitamab in a relapsed/refractory (R/R) patient population and looks forward to further data, which he hopes will confirm the efficacy of this agent. This interview took place during the 18th International Conference on Malignant Lymphoma (18-ICML) in Lugano, Switzerland.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
The initial study, the 179 study, was originally designed just to look at glofitamab in multiple cohorts of patients with non-Hodgkin lymphoma. There was a spin-off cohort looking at patients with mantle cell lymphoma for which initially we saw a very impressive response rate and I think in the context of what we were seeing with other agents in the field it spurred an expansion of this cohort to get further sort of efficacy and duration of response...
The initial study, the 179 study, was originally designed just to look at glofitamab in multiple cohorts of patients with non-Hodgkin lymphoma. There was a spin-off cohort looking at patients with mantle cell lymphoma for which initially we saw a very impressive response rate and I think in the context of what we were seeing with other agents in the field it spurred an expansion of this cohort to get further sort of efficacy and duration of response.
So from what we did publish, ideally if we look at this patient population, we did see that patients who were in complete remission at the end of treatment, a fair number of these patients, over 50% of these patients, have remained and maintained in remission, which fares very favorably with what we see with even the cellular therapy such as brexu-cel and liso-cel. Moving forward, obviously we’ll continue to generate more, hopefully, durability of response to get more long-term follow-up of this initial cohort, which will hopefully be some sort of harbinger of what we can expect to see with the final readout of the GLOBRYTE study, which will fully evaluate the efficacy of this in a randomized fashion. Obviously, it’s very hard to truly determine the efficacy of treatment options in single-arm studies.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
